How this Nasdaq-U.K.-listed Chinese biotech is revolutionizing cancer treatment By: MarketWatch September 17, 2020 at 12:55 PM EDT Chi-Med has been granted three U.S. Food and Drug Administration Fast Track Designations for its cancer drugs. Read More >> Related Stocks: Eli Lilly Hutchmed China Ltd ADR Procter & Gamble